urothelial carcinoma

By Targets:	ADC Antibody (1) Antibody-Drug Conjugates (ADCs) (2) Cholinesterase (ChE) (1) FGFR (1) Isotope-Labeled Compounds (1) Nectin-4 (5) Parasite (1) PD-1/PD-L1 (3)
By Research Areas:	Cancer (11) Inflammation/Immunology (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99384

Vofatamab B-701; MFGR-1877S; RG-7444	FGFR	Cancer
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC) .

HY-P10524A

N188 TFA	Nectin-4	Cancer
N188 TFA is a radioligand based on a bicyclic peptide backbone that targets nectin-4, a protein overexpressed in many tumors. N188 TFA can be efficiently radiolabeled to 68Ga-N188, a radioisotope suitable for positron emission tomography (PET) imaging. The development of N188 TFA and its radiolabeled form 68Ga-N188 can be used for the diagnosis and treatment of tumors such as urothelial carcinoma .

HY-P99016

Enfortumab	ADC Antibody Nectin-4	Cancer
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

HY-P99016A

Enfortumab vedotin-ejfv	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma .

HY-P99016B

Enfortumab vedotin-ejfv (solution)	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma .

HY-B0860

Diuron	Others	Cancer
Diuron is a phenylurea herbicide that inhibits photosynthesis by preventing the formation of ATP and NADH. Diuron (2,500 ppm, dietary) increases the incidence of urinary bladder urothelial carcinomas in male and female mice by 73 and 27%, respectively.

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	PD-1/PD-L1	Cancer
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .

HY-P10524

N188	Nectin-4	Cancer
N188 is a radioligand based on a bicyclic peptide backbone that targets nectin-4, a protein overexpressed in many tumors. N188 can be efficiently radiolabeled to 68Ga-N188, a radioisotope suitable for positron emission tomography (PET) imaging. The development of N188 and its radiolabeled form 68Ga-N188 can be used for the diagnosis and treatment of tumors such as urothelial carcinoma .

HY-119419S

Pirimicarb-d6	Cholinesterase (ChE) Parasite Isotope-Labeled Compounds	Others
Pirimicarb-d₆ is the deuterium labeled Diuron. Diuron is a phenylurea herbicide that inhibits photosynthesis by preventing the formation of ATP and NADH. Diuron (2,500 ppm, dietary) increases the incidence of urinary bladder urothelial carcinomas in male

HY-B0860R

Diuron (Standard)	Others	Cancer
Diuron (Standard) is the analytical standard of Diuron. This product is intended for research and analytical applications. Diuron is a phenylurea herbicide that inhibits photosynthesis by preventing the formation of ATP and NADH. Diuron (2,500 ppm, dietary) increases the incidence of urinary bladder urothelial carcinomas in male and female mice by 73 and 27%, respectively.

HY-P99052

Tislelizumab 2 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .

Cat. No.	Product Name	Target	Research Area

HY-P10524A

N188 TFA	Nectin-4	Cancer
N188 TFA is a radioligand based on a bicyclic peptide backbone that targets nectin-4, a protein overexpressed in many tumors. N188 TFA can be efficiently radiolabeled to 68Ga-N188, a radioisotope suitable for positron emission tomography (PET) imaging. The development of N188 TFA and its radiolabeled form 68Ga-N188 can be used for the diagnosis and treatment of tumors such as urothelial carcinoma .

HY-P10524

N188	Nectin-4	Cancer
N188 is a radioligand based on a bicyclic peptide backbone that targets nectin-4, a protein overexpressed in many tumors. N188 can be efficiently radiolabeled to 68Ga-N188, a radioisotope suitable for positron emission tomography (PET) imaging. The development of N188 and its radiolabeled form 68Ga-N188 can be used for the diagnosis and treatment of tumors such as urothelial carcinoma .

Cat. No.	Product Name	Target	Research Area

HY-P99384

Vofatamab B-701; MFGR-1877S; RG-7444	FGFR	Cancer
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC) .

HY-P99016

Enfortumab	ADC Antibody Nectin-4	Cancer
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

HY-P99016B

Enfortumab vedotin-ejfv (solution)	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma .

HY-P99594

Socazolimab ZKAB001; STI-1014; STI-A1014	PD-1/PD-L1	Cancer
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .

HY-P99052

Tislelizumab 2 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .

Cat. No.	Product Name	Chemical Structure

HY-119419S

Pirimicarb-d6
Pirimicarb-d₆ is the deuterium labeled Diuron. Diuron is a phenylurea herbicide that inhibits photosynthesis by preventing the formation of ATP and NADH. Diuron (2,500 ppm, dietary) increases the incidence of urinary bladder urothelial carcinomas in male

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Name
Email *

	Sorry, but the email address you supplied was invalid.